General and specific cognitive deficits in schizophrenia: Goliath defeats David?
- PMID: 18472089
- PMCID: PMC4332801
- DOI: 10.1016/j.biopsych.2008.04.005
General and specific cognitive deficits in schizophrenia: Goliath defeats David?
Abstract
Background: Our earlier work suggested that the cognitive performance impairment in individuals with schizophrenia relative to healthy control subjects was generalized, cutting across narrower cognitive ability dimensions. Current analyses sought to extend these findings.
Methods: Seventeen neuropsychological variables, available for 148 schizophrenia subjects and 157 control subjects, were subjected to structural equation modeling. Analyses incorporated a hierarchical model, grouping the variables into six familiar cognitive domains and linking these to a higher-order, general cognitive ability factor. We added diagnosis to the model as a grouping factor and estimated loadings from diagnosis to the general cognitive factor and, separately, to the domain factors.
Results: The fit of the final model was good (e.g., Non-Normed Fit Index [NNFI] = .988). Approximately 63.6% of the diagnosis-related variance in cognitive performance was mediated through the general factor, with smaller direct effects on verbal memory (13.8%) and processing speed (9.1%).
Conclusions: The schizophrenia cognitive deficit is largely generalized across performance domains, with small, direct effects of diagnostic group confined to selected domains. This generalized deficit sometimes has been seen as a function of the psychometric limitations of traditional cognitive test batteries. Alternatively, it may be a fundamental manifestation of schizophrenia, with similarly general neurobiological underpinnings.
Conflict of interest statement
Drs. Dickinson and Ragland report no biomedical financial interests or potential conflicts of interest. Dr. Gold receives royalty payments from the Brief Assessment of Cognition in Schizophrenia test battery and has served as a consultant for Pfizer, Solvay, and AstraZeneca. Dr. Gur serves as consultant, and his laboratory performs studies for Merck. He has investigator-initiated grants from AstraZeneca, and he is consultant to Brain Resource Center and Current Designs, Inc. (manufacturers of a fiber optic response pad used in functional magnetic resonance imaging [fMRI] studies).
Figures
References
-
- Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004;72:29–39. - PubMed
-
- Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006;31:2033–2046. - PubMed
-
- Jensen AR. Psychometric g: Definition and substantiation. In: Sternberg RJ, Grigorenko EL, editors. The General Factor of Intelligence. Mahwah, NJ: Lawrence Earlbaum; 2002. pp. 39–54.
-
- Dickinson D, Iannone VN, Wilk CM, Gold JM. General and specific cognitive deficits in schizophrenia. Biol Psychiatry. 2004;55:826–833. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
